Dendreon | ProvONE | NCT06134232

About

Metastatic castrate-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer that has spread beyond the prostate and no longer responds to standard hormone-reducing therapy. It is among the leading causes of cancer-related death in men. While several treatments can extend survival, mCRPC remains incurable. PROVENGE® (sipuleucel-T) is an FDA-approved immunotherapy that uses the patient’s own immune cells to fight prostate cancer. Finding ways to boost the immune response from this therapy is an important research goal.

Purpose

This open-label study investigates whether an additional “booster” infusion of sipuleucel-T can further enhance the immune response in men with mCRPC who have already completed the standard three-infusion PROVENGE® treatment course. The primary goal is to measure changes in immune response markers following the booster. Researchers hope this approach amplifies the anti-cancer immune effect and improves disease control. Secondary goals include assessing the safety of the additional infusion.

Eligibility

• Men (age ≥18) with asymptomatic or minimally symptomatic mCRPC who are clinically indicated for PROVENGE®
• Not currently using chronic immunosuppressive therapy (e.g., systemic steroids, anti-TNF agents)

Benefits

If you qualify for the study, all study-related medical care and treatment will be provided to you at no cost. You may receive a stipend for your participation in the study.

Send us a message if you are interested in participating in a study.